Sign in Subscribe

crc-research

A collection of 93 issues

ctDNA Among Novel Screening Biomarkers

Skip to content The CRC Digest ctDNA Among Novel Screening Biomarkers Systematic review highlights circulating tumor DNA as a candidate for blood-based colorectal cancer screening. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest

AI-Based MSI Detection Shows Promise

Skip to content The CRC Digest AI-Based MSI Detection Shows Promise Meta-analysis confirms deep learning tools can accurately identify MSI-H status, which determines eligibility for immunotherapy. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC

CRC Research Finding

Skip to content The CRC Digest ▪ Review Identifies Promising Blood-Based Biomarkers for CRC Screening A systematic review examined novel blood tests, including circulating tumor DNA (ctDNA), that could help detect colorectal cancer and precancerous conditions earlier through less invasive screening methods. (Clinical Colorectal Cancer) This content is informational only and

This Week in CRC Research — April 19, 2026

Weekly colorectal cancer research intelligence

FIERCE Study: Trifluridine/Tipiracil With Radiation in Rectal Cancer

Skip to content The CRC Digest FIERCE Study: Trifluridine/Tipiracil With Radiation in Rectal Cancer — Clinical Colorectal Cancer Results from the FIERCE study have been published in Clinical Colorectal Cancer. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

Phase II: Pembrolizumab Plus Capecitabine and Bevacizumab in MSS Metastatic CRC

Skip to content The CRC Digest Phase II: Pembrolizumab Plus Capecitabine and Bevacizumab in MSS Metastatic CRC — Clinical Colorectal Cancer Clinical Colorectal Cancer. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

AZUR-4: Neoadjuvant Dostarlimab Plus Chemotherapy in MSS Colon Cancer

Skip to content The CRC Digest AZUR-4: Neoadjuvant Dostarlimab Plus Chemotherapy in MSS Colon Cancer — Clinical Colorectal Cancer The AZUR-4 trial protocol has been published in Clinical Colorectal Cancer. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC

Long-Term Results: Adjuvant Chemotherapy After Liver Metastasis Surgery (JCOG0603)

Skip to content The CRC Digest Long-Term Results: Adjuvant Chemotherapy After Liver Metastasis Surgery (JCOG0603) — Journal of Clinical Oncology Journal of Clinical Oncology. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Circulating Tumor DNA Testing May Increase Fear of Recurrence in Some Colorectal Cancer Survivors

Skip to content The CRC Digest ♥ LIVING WITH CRC Circulating Tumor DNA Testing May Increase Fear of Recurrence in Some Colorectal Cancer Survivors — Psycho-Oncology Researchers interviewed colorectal cancer survivors enrolled in the DYNAMIC trials, which used ctDNA testing to guide decisions about adjuvant chemotherapy after surgery. While many patients valued

HER2 Amplification May Predict Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Skip to content The CRC Digest ▸ TREATMENT HER2 Amplification May Predict Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer — ESMO Gastrointestinal Oncology An exploratory analysis from the CAPRI-2 GOIM trial examined HER2 gene alterations in patients with RAS/BRAF wild-type, microsatellite stable metastatic colorectal cancer treated with FOLFIRI chemotherapy plus